LIFECORE BIOMEDICAL, INC. annual report, Q2 FY2009

Business Context and Reporting Period

Company: Landec Corporation (Note: Metadata referenced "LIFECORE BIOMEDICAL, INC." but the filing text is for Landec Corporation, ticker LNDC).

Reporting Period: Fiscal year ended May 31, 2009.

Business Overview: Landec designs, develops, and sells temperature-activated specialty polymer products. Operations are divided into three core segments:

  • Food Products Technology: Operated through subsidiary Apio, Inc., utilizing proprietary BreatheWay packaging for fresh-cut and whole produce to extend shelf life.
  • Commodity Trading: Buy-sell business for whole fruit and vegetable products, primarily exporting to Asia and selling domestically to Wal-Mart.
  • Technology Licensing: Licensing of Intellicoat seed coating technology (primarily to Monsanto) and Intelimer polymers for industrial and personal care applications.

Key Financial Metrics

Metric (in thousands) Fiscal 2009 Fiscal 2008
Total Revenues $235,938 $238,527
Gross Profit $34,280 $38,228
Operating Income $12,598 $15,176
Net Income $7,730 $13,542
Diluted EPS $0.29 $0.50
Cash and Cash Equivalents $43,459 $44,396
Total Debt $0 $0
Operating Cash Flow $9,435 $17,520

Margins: Gross margin decreased to approximately 14.5% in 2009 from 16.0% in 2008. Net income margin decreased to 3.3% from 5.7%.

Material Changes vs. Prior Period

  • Revenue Decline: Total revenues decreased 1% to $235.9 million. The Food Products Technology segment saw a 2% decline, driven by a 1% drop in value-added unit sales and a 23% drop in Apio Packaging revenues due to amended minimum payments from Chiquita.
  • Profitability Compression: Net income fell 43% to $7.7 million. This was driven by a 10% decrease in gross profit (due to higher raw material costs and lower packaging revenues) and a significant increase in the effective tax rate from 20% to 42% as the company utilized its net operating loss carryforwards.
  • Segment Performance:
    • Food Products Technology: Gross profit declined 16% to $23.4 million.
    • Commodity Trading: Revenues remained flat, but gross profit increased 6% to $3.7 million due to a shift toward higher-margin vegetable products.
    • Technology Licensing: Revenues increased 5% to $7.2 million, primarily from the Monsanto license agreement.
  • Debt: The company terminated its $7.0 million revolving line of credit with Wells Fargo in May 2009. The company ended the period with no debt.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

  • Management expects capital expenditures of approximately $6.0 million to $6.5 million in fiscal 2010, primarily for a 40,000 square foot expansion of the Apio processing plant.
  • The company believes its cash from operations and existing cash reserves are sufficient to finance requirements for at least the next twelve months.
  • Future growth depends on the commercialization of new products, particularly in the fresh-cut produce market and the expansion of the Chiquita avocado packaging agreement.

Risks and Contingencies:

  • Economic Conditions: The filing highlights risks associated with the economic slowdown, including reduced demand, conservative purchasing by customers, and potential credit issues for vendors and growers.
  • Customer Concentration: The top five customers accounted for 46% of revenues, with Costco Wholesale Corporation alone representing 21%.
  • Supply Chain: Dependence on single-source suppliers for certain raw materials (monomers) and single-location manufacturing for Apio (Guadalupe, CA) poses operational risks.
  • Intellectual Property: Success depends on maintaining patent protection and avoiding infringement claims.
  • Regulatory: Operations are subject to FDA, USDA, and environmental regulations. A determination that BreatheWay packaging is a food additive requiring FDA approval could materially impact the business.

Investor Verification Checklist

  • Verify the sustainability of the 42% effective tax rate in future periods now that net operating loss carryforwards have been utilized.
  • Monitor the performance of the Chiquita licensing agreement, specifically the minimum gross profit thresholds for bananas and avocados.
  • Assess the impact of the 21% revenue concentration with Costco Wholesale Corporation on future pricing power and volume stability.
  • Review the progress of the Apio facility expansion and its impact on capacity and capital expenditure burn rate.
  • Confirm the status of the Monsanto license agreement regarding the potential $10 million purchase option for Landec Ag.